Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 3/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL421819 | 1.00 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| Water SCHEMBL6549696 | 0.98 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| Hydrochloric Acid SCHEMBL18209371 | 0.94 | DGKA (0.47) | MGLLEPHX2DGKAPRKCACNR2 | |
| Hydrochloric Acid SCHEMBL888280 | 0.94 | DGKA (0.47) | MGLLEPHX2DGKAPRKCACNR2 | |
| SCHEMBL1044582 | 0.93 | DGKA (0.48) | MGLLEPHX2DGKAPRKCACNR2 | |
| Hydrochloric Acid SCHEMBL3281364 | 0.87 | MGLL (0.45) | MGLLEPHX2DGKAPRKCAPRKCE | |
| Hydrochloric Acid SCHEMBL421820 | 0.87 | MGLL (0.45) | MGLLEPHX2DGKAPRKCAPRKCE | |
| SCHEMBL441410 | 0.86 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| SCHEMBL19133947 | 0.86 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| SCHEMBL16607665 | 0.86 | DGKA (0.45) | MGLLEPHX2DGKAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292106-B1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2021-10-27 | — | — | EP | claimed |
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2019-11-19 | — | — | US | claimed |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2018-05-31 | — | — | US | claimed |
| EP-3292106-A1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | Bayer Animal Health GmbH (DE) | 2018-03-14 | — | — | EP | claimed |
| WO-2016177693-A1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-11-10 | — | — | WO | claimed |
| US-9089537-B2 | Subunit vaccines for herpes viruses and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSLYVANIA (US) | 2015-07-28 | — | — | US | claimed |
| US-20030229040-A1 | Cationic liposomal delivery system and therapeutic use thereof | GEORGETOWN UNIVERSITY | 2003-12-11 | — | — | US | claimed |
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | WOODLE MARTIN C (US) | 2003-09-04 | — | — | US | claimed |
| US-6559129-B1 | Administering a radiosensitizing effective amount of a cationic liposomal formulation comprising at least one cationic lipid to radiosensitize raf oncogene expressing tumor tissue in a subject in need of such treatment | GEORGETOWN UNIVERSITY | 2003-05-06 | — | — | US | claimed |
| EP-3292106-B1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-0955999-B1 | NOVEL LIPOSOME COMPLEXES FOR INCREASED SYSTEMIC DELIVERY | US GOV HEALTH & HUMAN SERV (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1047774-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6126965-A | CATIONIC LIPOSOMES OF DIMETHYLDIOCTADECYLAMMONIUM BROMIDE, PHOSPHATIDYLCHOLINE AND CHOLESTEROL WITH ENCAPSULATION | GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE (US) | 2000-10-03 | — | — | US | disclosed |
| US-6120799-A | Cationic lipid compositions targeting angiogenic endothelial cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999036514-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE (US) | 1999-07-22 | — | — | WO | disclosed |
| US-5837283-A | Cationic lipid compositions targeting angiogenic endothelial cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | IPO8, IPO9, IPO7 | MGLL 198/4885EPHX2 1872/4885DGKA 99/4885 |
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | FUS, HNRNPUL2, HNRNPH1 | MGLL 3014/4885EPHX2 4021/4885DGKA 2014/4885 |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | IPO8, IPO9, IPO7 | MGLL 142/4885EPHX2 2297/4885DGKA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.